Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15789507 | 0.82 | POLB (0.48) | POLBHSD17B10MAPTMAPK1CA12 | |
| SCHEMBL22538597 | 0.80 | POLB (0.47) | POLBHSD17B10MAPTMAPK1CA12 | |
| SCHEMBL27101554 | 0.79 | POLB (0.46) | POLBHSD17B10MAPTMAPK1CA12 | |
| SCHEMBL9272657 | 0.78 | KCNA5 (0.42) | SLC6A7CA1CA2CA9CYP2C19 | |
| SCHEMBL1031875 | 0.77 | CA12 (0.46) | POLBHSD17B10MAPTMAPK1CA12 | |
| SCHEMBL440638 | 0.77 | POLB (0.58) | POLBHSD17B10MAPTMAPK1KDM4E | |
| SCHEMBL31490354 | 0.77 | POLB (0.58) | POLBHSD17B10MAPTMAPK1KDM4E | |
| SCHEMBL23171270 | 0.76 | POLB (0.43) | POLBHSD17B10MAPK1CA12CA1 | |
| SCHEMBL19105546 | 0.76 | POLB (0.43) | POLBHSD17B10MAPTMAPK1CA12 | |
| SCHEMBL12889037 | 0.74 | PTPN11 (0.40) | POLBMAPTKDM4EALDH1A1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12264156-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | GALAPAGOS NV (BE) | 2025-04-01 | — | — | US | disclosed |
| US-20220402911-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2022-12-22 | — | — | US | disclosed |
| US-20220402911-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2022-12-22 | — | — | US | disclosed |
| WO-2019238424-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2019-12-19 | — | — | WO | disclosed |
| US-6924300-B2 | Oxyiminoalkanoic acid derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-08-02 | — | — | US | disclosed |
| EP-1077957-B1 | OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2004-08-04 | — | — | EP | disclosed |
| EP-1428531-A1 | Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-06-16 | — | — | EP | disclosed |
| EP-1417196-A1 | DNA-PK INHIBITORS | Cancer Research Technology Limited (GB) | 2004-05-12 | — | — | EP | disclosed |
| US-6686475-B2 | THIAZOLIDINEDIONE DERIVATIVES HAVING HYPOGLYCAEMIC AND HYPOLIPIDAEMIC ACTIVITIES | BEECHAM GROUP P.L.C. (GB) | 2004-02-03 | — | — | US | disclosed |
| US-20030186985-A1 | Oxyiminoalkanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-0306228-B1 | Substituted thiazolidinedione derivatives | BEECHAM GROUP PLC (GB) | 1999-11-17 | — | — | EP | disclosed |
| US-5756525-A | USING A THIAZOLIDINEDIONE COMPOUND | BEECHAM GROUP PLC (GB) | 1998-05-26 | — | — | US | disclosed |
| EP-0842925-A1 | Substituted thiazolidinedione derivatives | BEECHAM GROUP PLC (GB) | 1998-05-20 | — | — | EP | disclosed |
| US-5646169-A | ADMINISTERING SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVES TO HUMANS OR OTHER MAMMALS | BEECHAM GROUP P.L.C. (GB) | 1997-07-08 | — | — | US | disclosed |
| US-5521201-A | SUBSTITUTED-THIAZOLIDINEDIONE DERIVATIVES | BEECHAM GROUP P.L.C. | 1996-05-28 | — | — | US | disclosed |
| US-5260445-A | Hypoglycemic | BEECHAM GROUP P.L.C. (GB) | 1993-11-09 | — | — | US | disclosed |
| US-5232925-A | Treating hypertension | BEECHAM GROUP P.L.C. (GB) | 1993-08-03 | — | — | US | disclosed |
| US-5194443-A | Thiazolinediones, Hypoglycemic Agents, Antilipemic Agents | BEECHAM GROUP P.L.C. (GB) | 1993-03-16 | — | — | US | disclosed |
| US-5002953-A | Substituted Thiazolidinedione Derivatives | BEECHAM GROUP P.L.C. (GB) | 1991-03-26 | — | — | US | disclosed |
| EP-0306228-A1 | Substituted thiazolidinedione derivatives | BEECHAM GROUP PLC (GB) | 1989-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186985-A1 | Oxyiminoalkanoic acid derivatives | GPR119, IRS1, CPT1A | POLB 2928/4885HSD17B10 20/4885MAPT 4852/4885 |
| US-20220402911-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | IL1A, TNF, IL6 | POLB 1280/4885HSD17B10 1591/4885MAPT 4632/4885 |
| US-12264156-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | TNF, IL1A, COL1A1 | POLB 1397/4885HSD17B10 1668/4885MAPT 4564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.